View More Recent Stories

Feb 15, 2021 09:13PM Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer’s Disease
Feb 10, 2021 04:06PM Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion
Jan 26, 2021 08:00AM Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones
Dec 4, 2020 07:01AM Cortexyme (CRTX) Reports Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim Analysis
Dec 4, 2020 07:00AM Cortexyme’s Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim Analysis
Nov 12, 2020 04:30PM Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business Update
Nov 5, 2020 08:00AM Cortexyme Presents an Update and Baseline Data from the Phase 2/3 GAIN Trial of Atuzaginstat at CTAD 2020, the Clinical Trials on Alzheimer’s Disease Conference
Oct 19, 2020 08:00AM Cortexyme Announces Upcoming Data Presentations at November 2020 Conferences
Sep 24, 2020 08:04AM Cortexyme (CRTX) Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 Patients
Sep 24, 2020 08:00AM Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 Patients
Sep 9, 2020 08:00AM Cortexyme to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
Aug 27, 2020 08:01AM Cortexyme (CRTX) Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office
Aug 27, 2020 08:00AM Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office
Aug 17, 2020 08:00AM Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update
Aug 14, 2020 08:00AM Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Reached Enrollment Milestone of 500 Patients
Aug 6, 2020 04:05PM Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020
Jul 29, 2020 08:00AM Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020
Jul 28, 2020 06:09PM Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers As
Jul 22, 2020 08:00AM Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020
May 27, 2020 08:00AM Cortexyme to Present at the Jefferies Virtual Healthcare Conference on June 2, 2020
May 12, 2020 04:05PM Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update
May 7, 2020 08:00AM Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020
May 6, 2020 08:30AM Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimer’s-Like Pathology in the Journal of Alzheimer’s Disease
Apr 30, 2020 04:05PM Cortexyme Appoints Caryn McDowell, J.D. as Chief Legal and Administrative Officer and Corporate Secretary
Apr 6, 2020 08:30AM Cortexyme to Present at the LifeSci Capital Alpha Series Virtual Conference on April 9, 2020
Apr 2, 2020 08:00AM Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer’s Pathology at Advances in Alzheimer’s and Parkinson’s Therapies Virtual Focus Meeting 2020
Mar 17, 2020 08:00AM Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Mar 16, 2020 08:00AM Cortexyme Announces Gain Trial in Alzheimer’s Disease Has Reached Enrollment Milestone of 300 Patients
Feb 13, 2020 08:26AM Cortexyme (CRTX) Provides Regulatory Update for COR388 Development Program in Alzheimer’s Disease
Feb 13, 2020 08:00AM Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimer’s Disease
Jan 30, 2020 08:18AM Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Company’s Lead Investigational Medicine
Jan 13, 2020 08:08AM Cortexyme (CRTX) Commences Open-Label Extension Study for GAIN Trial of COR388 in Alzheimer’s Disease
Jan 13, 2020 08:00AM  Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer’s Disease
Jan 8, 2020 04:05PM Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020
Dec 7, 2019 01:00PM Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimer’s Disease
Nov 26, 2019 04:05PM Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
Nov 12, 2019 04:05PM Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update
Nov 1, 2019 08:00AM Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimer’s Disease 2019
Sep 26, 2019 08:00AM Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial
View More Recent Stories